Suchergebnisse

This report introduces and analyzes innovation and competition policy issues associated with the pharmaceutical industry. It begins with a review of the Hatch-Waxman Act and its implications upon the availability of generic substitutes for brand-name medications. The report then turns to a basic review of the antitrust law. It then addresses judicial developments with respect to reverse payment settlements and product hopping. The report closes with a summary of congressional issues and possible alternatives.

This report discusses FDA Regulation of Biologics, Biosimilars and Regulatory Exclusivities, Patent Dispute Resolution and Current Issues.

The report is about Compulsory Licensing of Patented Inventions. It discusses a number of international agreements to which the United states and its trading partners are signatories, including the Paris convention for the Protection of industrial Property.

This report introduces and analyzes innovation policy issues concerning pharmaceutical patent litigation settlements, including pharmaceutical patent litigation procedures under the Hatch-Waxman Act, the concept of reverse payment settlements, the status of reverse payment settlements under the antitrust laws, and congressional issues and alternatives.

This report reviews the relationship between Congress and the courts in patent reform. It begins by offering a summary of the patent system. The report then discusses a number of topics that have been the subject of both judicial and legislative consideration. The current state of the law is then contrasted with legislative reform proposals before previous Congresses. The report closes with observations concerning the subtle interaction between legislative, administrative, and judicial actors within the patent system and their impact upon the U.S. innovation environment.

This report considers the current dispute between the research-based pharmaceutical industry, on one hand, and certain foreign governments, patient advocacy groups and generic manufacturers, on the other, regarding patented HIV/AIDS pharmaceuticals. It then describes contemporary international controversies regarding patents on HIV/AIDS drugs and the potential consequences of these disputes for entrepreneurial drug companies.

In der Studie über die zunehmende Militarisierung der sowjetischen Akademie der Wissenschaften gibt der Autor zunächst einen Überblick über die Entwicklung der Einbeziehung der Akademie in das System der wissenschaftlich-technologischen Forschung sowie der militärischen Forschung und Entwicklung zur Industrialisierung und Wiederaufrüstung des Landes. Untersucht wird sodann die gegenwärtige Beteiligung der Akademie an militärbezogenen Projekten sowie ihre Rolle im militärischen Forschungs- und Entwicklungsprozeß, gerade auch im Hinblick auf zukünftige Veränderungen in der militärischen Forschungs- und Entwicklungspolitik der UdSSR. Abschließend befaßt sich der Autor mit den Implikationen der weiteren systemischen und personellen Entwicklung der Akademie für ihre zukünftige Beteiligung am militärischen Forschungs- und Entwicklungsprozeß. (BIOst-Klk)